TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
VNDA

Vanda Pharmaceuticals Inc

Healthcare · Biotechnology

5.10$ +0.4% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement VNDA
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
3.2% 21.3% 16.9% 10.8% 10.6% 10.8% 9.4% 9.5% 9.5% 9.1% 5.7% 6.0%
96.8% 78.7% 83.1% 89.2% 89.4% 89.2% 90.6% 90.5% 90.5% 100.0% 94.3% 94.0%
38.3% 26.5% 20.0% 23.4% 22.6% 21.4% 22.4% 28.0% 33.7% 39.9% 37.4% 50.6%
158.8% 73.8% 67.4% 74.2% 54.8% 55.7% 51.5% 43.7% 52.6% 63.4% 72.7% 110.1%
211.6% 115.2% 95.8% 99.4% 78.1% 79.2% 79.6% 74.8% 88.0% 107.2% 114.8% 163.9%
40.0% -36.6% -12.7% -10.2% 11.3% 10.0% 11.0% 15.7% 2.5% -7.2% -20.5% -70.0%
0.0% 0.0% 0.0% 0.0% 0.0% 2.7% 1.8% 0.1% 2.0%
40.2% -36.3% -12.3% -9.3% 13.1% 12.8% 12.8% 15.8% 4.4% 3.3% -11.5% -64.2%
-154.7% 0.0% 0.1% 0.1% 0.1% -38.1% 3.4% 3.4% 2.0% 2.0% -2.0% 37.9%
40.2% -36.3% -12.3% -9.4% 13.1% 50.9% 9.4% 12.3% 2.5% 1.3% -9.5% -102.0%
-109.2% -24.2% -4.6% -8.4% 12.8% 11.3% 13.9% 16.8% 5.5% -7.2% -7.4% -58.6%

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?